옵션 체인은 다양한 행사가격과 만기일에 대한 Genmab의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Genmab에 대한 시장 심리를 평가합니다..

Genmab (NASDAQ:GMAB) 주식, 옵션 체인

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Genmab AS

ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) reported quarterly earnings of $0.01 per share. This is a 83.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $324.70 million in sales this quarter. This is a 5.67 percent decrease over sales of $344.22 million the same period last year.

Earnings

ZKH Group Q4 Adj $0.01 Down From $0.06 YoY, Sales $324.70M Down From $344.22M YoY

Keefe, Bruyette &amp; Woods analyst Vasundhara Govil upgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Market Perform to Outperform and lowers the price target from $87 to $80.

Upgrades

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Upgrades Block to Outperform, Lowers Price Target to $80

Just days ahead of its expected unveiling, Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Google&#8217;s Pixel 9a has appeared in full in hands-on video reviews, revealing the budget phone's refreshed design and upgraded specs.
What Happened: Two YouTubers, Sahil Karoul and The Mobile Central, posted in-depth video reviews of what appears to be the Pixel 9a, showcasing the device from every angle.
The leaks confirm earlier rumors, including a flatter back design that eliminates the prominent camera bump seen in previous models. The Pixel 9a also sports a 6.3-inch display with noticeable bezels and houses a significantly larger 5,100mAh battery.
The videos highlight camera samples captured with the phone's rumored 48-megapixel main camera, 13-megapixel ultrawide sensor, and 13-megapixel front-facing camera.
See Also: <a href="https://www.benzinga.com/25/02/43646615/top-analyst-says-metas-ai-push-could-add-100-per-share-while-tesla-faces-ev-headwindswhy-hes-still-bullish-on-musks-robotics-vision">Meta&#8217;s AI Push Could Add $100 Per Share While Tesla Faces EV Headwinds: Top Analyst</a>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Exclusive Google Pixel 9a Unboxing with Benchmark &#x7C;&#x7C; Camera shots&#x7C;&#x7C; Gameplay &#x7C;&#x7C; Speaker &amp; Display" width="500" height="281" src="https://www.youtube.com/embed/S64oWRtVOA0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
While daytime shots appear sharp and vibrant, The Mobile Central noted a dip in video quality under low-light conditions.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Pixel 9A Review: Is Google&#039;s Budget Phone Worth It?" width="500" height="281" src="https://www.youtube.com/embed/tnrLSRT7CR0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
According to the available reports, Google is expected to officially unveil the Pixel 9a on March 19, with multiple color options including purple, pink, black, and white.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It's Important: With Google's <a href="https://in.benzinga.com/25/02/43479274/alphabet-q4-earnings-highlights-ai-cloud-youtube-momentum-continues-capex-guidance-sends-shares-lower">device and subscription revenue</a> hitting $11.6 billion in the fourth quarter—up from $10.8 billion a year prior—Pixel phones remain a growing part of the company's hardware strategy.
Alphabet reported $96.5 billion in total revenue for the fourth quarter, reflecting a 12% increase from the previous year. However, this figure fell slightly short of the Street consensus estimate of $96.6 billion.
Last month, Google also announced that its <a href="https://in.benzinga.com/25/02/43649987/google-io-2025-officially-set-for-may-20-21-heres-what-to-expect-from-ai-breakthroughs-to-the-future-of-android-and-pixel-9a">annual developer conference</a>, Google I/O 2025, will be held on May 20-21 at the Shoreline Amphitheater in Mountain View, California.
There were also speculations that Google would debut the Pixel 9a at the event. While the company has traditionally launched its Pixel "a" series at I/O, in 2024 it deviated from this pattern by unveiling the Pixel 8a through a marketing campaign instead.
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/media/25/02/43646042/elon-musks-97-4-billion-openai-takeover-bid-reportedly-not-received-by-chatgpt-parent-another-one-of-his-tactics-says-sam-altman">Elon Musk's $97.4 Billion OpenAI Takeover Bid Reportedly Not Received By ChatGPT Parent: ‘Another One Of His Tactics,' Says Sam Altman</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Tech

GOOG

GOOGL

Google Pixel 9a Leaks In Hands-On Videos Before Launch: Flat Design, 48MP Camera, 5,100mAh Battery Revealed

On Monday, Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) disclosed the launch of its Electron rocket, deploying five satellites <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44369244/successful-rocket-lab-launch-completes-deployment-of-full-kin-is-constellation-in-less-than-a-year" rel="noreferrer noopener">for French IoT operator Kinéis</a>.
This marks the completion of a five-launch deal, delivering Kinéis&#8217; 25-satellite constellation to Low Earth Orbit in under a year.
Rocket Lab founder and CEO Peter Beck said, &#8220;Many constellation operators wait years for their first mission, but we&#8217;ve deployed Kinéis&#8217; mission in under a year and with 100% dedicated launches where they have been able to select launch site, date, and orbital parameters allowing them to maximize coverage for each of their 25 spacecraft.&#8221;
Christophe Vassal &#8211; Chairman of the Supervisory Board of Kinéis, said, &#8221;On June 1st, we will launch our IoT satellite connectivity commercial services. This achievement marks the beginning of a new era for Kinéis, where the data collected by our constellation will unlock numerous opportunities for our clients and partners.&#8221;
Last week, Rocket Lab USA launched two software solutions&nbsp;to enhance the efficiency <a target="_blank" href="https://www.benzinga.com/25/03/44298251/rocket-lab-launches-next-gen-software-platforms-for-space-missions" rel="noreferrer noopener">of space mission operations</a>.
Investors can gain exposure to the stock via ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and Tidal ETF Trust II Pinnacle Focused Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCUS#NYSE">FCUS</a>).
Price Action: RKLB shares are up 0.89% at $19.27 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44349255/rocket-lab-launches-lightning-god-reigns-mission-for-japans-iqps-sets-sights-on-high-five-launch-just-three-days-later" target="_blank" rel="noreferrer noopener">Rocket Lab Launches &#8216;Lightning God Reigns&#8217; Mission, Sets Sights On &#8216;High Five&#8217; Launch Just Three Days Later</a></li>
</ul>
Image via Shutterstock.

ARKX

FCUS

RKLB

Rocket Lab Launches Final Kinéis Satellite, Enabling Global IoT Coverage

Goldman Sachs analyst Brooke Roach upgrades Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) from Neutral to Buy and raises the price target from $280 to $286.

Goldman Sachs Upgrades Ralph Lauren to Buy, Raises Price Target to $286

Billionaire investor David Tepper&#8217;s bullish call on Chinese stocks has yielded significant returns, with Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares rallying 40.44% since his Sep. 26 declaration that he was <a href="https://www.benzinga.com/markets/asia/24/12/42692036/billionaire-investors-michael-burry-david-tepper-could-benefit-from-chinas-stimulus-measures">buying &#8220;everything&#8221; in China</a>.
What Happened: BABA shares closed Monday at $147.57, up 4.59%, representing a substantial gain from $105.07 when Tepper made his bold prediction. The hedge fund manager cited exceptionally low valuations and China&#8217;s fiscal stimulus plans as key factors <a href="https://www.benzinga.com/markets/asia/24/12/42692036/billionaire-investors-michael-burry-david-tepper-could-benefit-from-chinas-stimulus-measures">behind his investment thesis</a>.
Regulatory filings show Appaloosa Management increased its stakes in major Chinese e-commerce names during the fourth quarter of 2024, with Alibaba remaining among the fund&#8217;s largest holdings. 
The firm also boosted positions in PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), JD.Com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and China-focused ETFs including iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) and KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>).
&#8220;When that came in, we got a little bit longer&#8230; more Chinese stocks,&#8221; Tepper said in September on CNBC&#8217;s &#8220;Squawk Box,&#8221; revealing he had exceeded his usual 10-15% allocation limits for Chinese investments.
While BABA has outperformed, performance has varied across Tepper&#8217;s China investments. JD.com has climbed 19% since September, but PDD Holdings declined 0.38% during the same period.
See Also: <a href="https://www.benzinga.com/markets/equities/25/03/44370649/ross-gerber-says-tesla-chair-robyn-denholm-paid-off-to-do-nothing-only-represents-elon-musk-while-pocketing-682-million">Ross Gerber Says Tesla Chair Robyn Denholm Paid Off To Do Nothing: &#8216;Only Represents&#8217; Elon Musk While Pocketing $682 Million</a>
Why It Matters: China&#8217;s economy beat forecasts with 5.4% growth in the fourth quarter of 2024, supported by Beijing&#8217;s stimulus measures including interest rate cuts. Investors now await details on additional fiscal support targeting consumer demand and <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41050711/stocks-rise-as-china-signals-more-stimulus-billionaire-david-tepper-bets-big-on-everythi">the troubled real estate market</a>.
Concerns remain about deflation and the potential impact of President Donald Trump&#8216;s 10% <a href="https://www.benzinga.com/personal-finance/25/03/44360075/retail-giant-target-which-relies-on-china-for-30-of-its-merchandise-warns-of-profit-hit-as-trumps-trade-war-bites">tariffs on Chinese imports</a>. Beijing has responded with targeted retaliatory duties, vowing to protect its interests against what it calls &#8220;bullying.&#8221;
Tepper isn&#8217;t alone in his China optimism. Michael Burry&#8216;s Scion Asset Management has also established significant positions in Chinese tech companies, with Alibaba representing 16.36% of the fund&#8217;s total investments, according to <a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">recent 13F filings</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44212672/jamie-dimon-cashed-out-234-million-in-jpmorgan-stock-warren-buffett-stockpiled-334-billion-in-cash-weeks-later-markets-crashed-coincidence" target="_blank" rel="noreferrer noopener">Jamie Dimon Cashed Out $234 Million In JPMorgan Stock, Warren Buffett Stockpiled $334 Billion In Cash — Weeks Later, Markets Crashed. Coincidence?</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

BABA

KWEB

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Billionaire Investor David Tepper's 'Everything' China Bet Pays Off With Alibaba Up 40% Since September

Evercore ISI Group analyst Daniel Markowitz initiates coverage on Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Outperform rating and announces Price Target of $75.

Initiation

TECH

Evercore ISI Group Initiates Coverage On Bio-Techne with Outperform Rating, Announces Price Target of $75

Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $1.95 by 36.41 percent. This is a 70.51 percent increase over earnings of $1.56 per share from the same period last year. The company reported quarterly sales of $1.93 billion which beat the analyst consensus estimate of $1.78 billion by 8.44 percent. This is a 18.78 percent increase over sales of $1.63 billion the same period last year.

Earnings Beats

ESLT

Elbit Systems Q4 2024 Adj EPS $2.66 Beats $1.95 Estimate, Sales $1.93B Beat $1.78B Estimate

President Donald Trump has publicly praised Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder&nbsp;and owner of The Washington&nbsp;Post, Jeff Bezos, for the significant changes he has implemented at the newspaper.
What Happened: President Trump,&nbsp;during an interview with television&nbsp;journalist Sharyl Attkisson, expressed his appreciation for Bezos&#8217; efforts to improve The Washington Post. &#8220;I&nbsp;think a guy like Bezos&nbsp;is — I've gotten to&nbsp;know him, and I think&nbsp;he's trying to do a&nbsp;real job. Jeff Bezos is&nbsp;trying to do a real&nbsp;job with The Washington Post,&#8221; Trump said.
Trump acknowledged a shift in Bezos&#8217; management of the Post during his first term, a change he claims was not previously evident. His comments refer to a series of high-profile decisions Bezos has made at the newspaper, including discontinuation of editorial support for a presidential candidate last fall, implementing a new directive for op-eds, and restructuring the Post&#8217;s newsroom. These changes have sparked significant backlash, leading to canceled subscriptions, staff departures, and accusations that Bezos is seeking to gain favor with Trump to further his business interests. Bezos has dismissed these claims, asserting that the changes at the Post are essential for regaining reader trust. SEE ALSO: <a href="https://www.benzinga.com/25/03/44370387/fed-put-on-standby-while-trump-put-may-be-kaput-analysts-expect-jerome-powell-to-pivot-to-a-measured-stance-amid-economic-uncertainty">Fed Put On Standby, While Trump Put May Be Kaput? Analysts Expect Jerome Powell To Pivot To A Measured Stance Amid Economic Uncertainty </a> Why It Matters: Bezos&#8217; overhaul of The Washington Post has been a topic of controversy. In February, the <a href="https://www.benzinga.com/25/02/43760885/jeff-bezos-owned-washington-post-turns-down-ad-campaign-that-asked-whos-running-this-country-donald-trump-or-elon-musk">newspaper rejected a provocative</a> "Fire Elon Musk" ad campaign by advocacy group Common Cause. This decision was part of a larger shift in the newspaper&#8217;s editorial policy. Also in February, Bezos, who attended Trump&#8217;s inauguration, announced a significant shift in the newspaper's opinion section, <a href="https://www.benzinga.com/general/social-media/25/02/43997193/jeff-bezos-washington-post-overhaul-draws-oligarch-remark-from-bernie-sanders-elon-musk-calls-amazon-founder-a-bravo">prioritizing viewpoints</a> supporting free markets and personal liberties. This move has drawn both praise and criticism, with some accusing Bezos of using the newspaper to advance his personal and business interests. Former Labor Secretary Robert Reich condemned this move as he said, &#8220;..it's not a win for free speech. It's a win for oligarchy." On the other hand, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk, responded to this move on X with "Bravo, Jeff Bezos!"
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="President Trump says immigration, the economy and the war in Ukraine are all on his short list." width="500" height="281" src="https://www.youtube.com/embed/Y16M67qNot8?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
READ MORE:
<ul>
<li><a href="https://www.benzinga.com/25/03/44370877/trump-ally-larry-ellisons-oracle-pledges-5-billion-to-boost-uks-ai-driven-cloud-infrastructure">Trump Ally Larry Ellison&#8217;s Oracle Pledges $5 Billion To Boost UK&#8217;s AI-Driven Cloud Infrastructure</a></li>
</ul>
Image via Shutterstock Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Politics

AMZN

TSLA

Trump Praises Jeff Bezos' Recent Moves With Washington Post: 'He's Trying To Do A Real Job'

Evercore ISI Group analyst Daniel Markowitz initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a In-Line rating and announces Price Target of $155.

RGEN

Evercore ISI Group Initiates Coverage On Repligen with In-Line Rating, Announces Price Target of $155

Tencent Music Entertainment Group Declared A Cash Dividend Of $0.09 Per Ordinary Share, Or $0.18 Per ADS, To Holders Of Record As Of Close Of Business On April 3

Tencent Music Entertainment Group Says It Has Recently Authorized A New Share Repurchase Program Under Which It May Repurchase Up To $1B Of Its Class A Ordinary Shares During 24-month Period Commencing From March 2025

As the Magnificent 7 companies have estimated a total capital expenditure of over $330 billion on the artificial intelligence infrastructure in 2025, there is a possibility that China&#8217;s AI breakthrough, despite chip shortage, could affect their targets, affecting profitability.
What Happened: The Magnificent 7 companies are widely expected to spend more than $330 billion on capex in 2025. While the chipmaker Nvidia Corp. hasn&#8217;t explicitly mentioned a target during its earnings call, the iPhone maker Apple Inc. broadly expects to spend <a href="https://www.benzinga.com/government/regulations/25/02/43912631/apple-forced-to-kiss-the-ring-expert-questions-whether-trump-pushed-the-iphone-maker-for-500-billion-investment">$500 billion</a> over the next four years.
The remaining companies, however, have provided a specific target for 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks</td>
<td>CAPEX Target For 2025</td>
<td>YTD Performance</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>&#8211;</td>
<td>-13.58%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>&#8211;</td>
<td>-12.24%</td>
</tr>
<tr>
<td>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td>$80 Billion</td>
<td>-7.14%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>$100 Billion</td>
<td>-11.12%</td>
</tr>
<tr>
<td>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</td>
<td>$75 Billion</td>
<td>-13.27%</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>$65 Billion</td>
<td>0.94%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>$11 Billion</td>
<td>-37.25%</td>
</tr>
</tbody>
</table>
</figure>
According to Edward Yardeni, the President of Yardeni Research, the &#8220;AI bubble&#8221; could be &#8220;bursting&#8221; as China continues to scale its AI-linked technology with inexpensive chips.
He said, &#8220;The fear now is that open-source large language models (LLMs) like DeepSeek and Manus, developed in China, require much less powerful semiconductors to operate.&#8221;
&#8220;If so, then AI capital spending will tumble along with the profit margins on AI systems,&#8221; adds Yardeni.
See Also: <a href="https://www.benzinga.com/25/03/44370387/fed-put-on-standby-while-trump-put-may-be-kaput-analysts-expect-jerome-powell-to-pivot-to-a-measured-stance-amid-">Fed Put On Standby, While Trump Put May Be Kaput? Analysts Expect Jerome Powell To Pivot To A Measured Stance Amid Economic Uncertainty</a>
Why It Matters: All Magnificent 7 companies have underperformed in 2025, except Meta Platforms Inc. The exchange-traded fund that tracks these seven companies, Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), has declined by 12.87% on a year-to-date basis.
Since DeepSeek was introduced on Jan. 24, MAGS has been down by 16.21% according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-1024x576.png" alt="" class="wp-image-828803" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18035026/Roundhill-since-DeepSeek.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The underperformance of Magnificent 7 companies can be attributed to "interest rate sensitivity," "unraveling trade tensions," and the high concentration of these stocks in the S&amp;P 500's market capitalization amid the market correction, according to John Murillo, the chief dealing officer at B2BROKER.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose on Monday. The SPY advanced 0.77% to $567.15, and the QQQ also jumped 0.65% to $482.77, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44354638/mark-cuban-advises-genz-to-spend-every-waking-minute-learning-about-ai-amid-disruption-heres-a-list-of-ai-investment-opportunities-for-long-term" target="_blank" rel="noreferrer noopener">Mark Cuban Advises GenZ To ‘Spend Every Waking Minute Learning About AI:' Here's A List Of AI Investment Opportunities For Long Term</a></li>
</ul>
Photo courtesy: Shutterstock

MAGS

MSFT

NVDA

AI Bubble Bursting? Magnificent 7's Profit Margins Face Pressure As 'Capital Spending Can Tumble' In 2025

Tencent Music Enter Gr Q4 Adj EPADS $0.20, Sales $1.02B Beat $1.01B Estimate

Aurora Mobile's SendCloud And SaleSmartly Forge Strategic Alliance To Elevate Global Email Marketing Performance

Evercore ISI Group analyst Daniel Markowitz initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Outperform rating and announces Price Target of $275.

Evercore ISI Group Initiates Coverage On West Pharmaceutical Servs with Outperform Rating, Announces Price Target of $275

General

Marriott's Subsidiary Ritz-Carlton Hotel Debuts In Suzhou City Near Shanghai

<h3>Companies Reporting Before The Bell</h3>
• Bitcoin Depot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $131.50 million. 
• United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) is expected to report quarterly loss at $0.41 per share on revenue of $9.50 million. 
• Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $185.00 million. 
• Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.68 million. 
• MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is expected to report earnings for its fourth quarter. 
• Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $211.54 million. 
• McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) is projected to report earnings for its fourth quarter. 
• ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) is estimated to report earnings for its fourth quarter. 
• HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $215.25 million. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is projected to report earnings for its fourth quarter. 
• UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report earnings for its fourth quarter. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $4.01 billion. 
• Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $1.01 billion. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report earnings for its fourth quarter. 
• OneConnect Financial Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NYSE">OCFT</a>) is likely to report earnings for its fourth quarter. 
• IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $413.76 million. 
• Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) is projected to report earnings for its fourth quarter. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is estimated to report quarterly earnings at $1.95 per share on revenue of $1.78 billion. 
• SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is expected to report earnings for its fourth quarter. 
• NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $1.66 billion. 
• Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $0.93 per share on revenue of $30 thousand. 
• Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is projected to report earnings for its fourth quarter. 
• LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is estimated to report earnings for its fourth quarter. 
• Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is likely to report earnings for its fourth quarter. 
• Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is projected to report quarterly loss at $1.19 per share on revenue of $26.90 million. 
• Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $23.69 million. 
• Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) is likely to report quarterly loss at $0.21 per share on revenue of $1.82 million. 
• OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is likely to report quarterly loss at $0.10 per share on revenue of $10.13 million. 
• HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $305.07 million. 
• StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $647.56 million. 
• Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) is likely to report quarterly loss at $0.25 per share on revenue of $272.22 million. 
• Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

ACXP

ATER

BEKE

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

CTRN

ETON

FLOC

HUYA

INKT

OABI

OCFT

ORLA

SNDL

SRFM

STNE

TIGR

TRVI

USEA

WALD

XPEV

Earnings Scheduled For March 18, 2025

Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/WSM/earnings">opening bell, on Wednesday, March 19.</a>
Analysts expect the San Francisco, California-based company to report quarterly earnings at $2.93 per share, up from $2.72 per share in the year-ago period. Williams-Sonoma projects quarterly revenue of $2.35 billion, compared to $2.28 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 20, 2024, Williams-Sonoma reported better-than-expected third-quarter financial results and approved a $1 billion stock repurchase authorization.
Williams-Sonoma shares rose 4.5% to close at $175.00 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/wsm/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Goldman Sachs analyst Kate McShane maintained a Neutral rating and increased the price target from $170 to $224 on Jan. 30, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating and raised the price target from $170 to $195 on Jan. 21, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Wells Fargo analyst Zachary Fadem maintained an Equal-Weight rating and raised the price target from $165 to $185 on Jan. 6, 2025. This analyst has an accuracy rate of 84%.</li>
<li>Wedbush analyst Seth Basham maintained a Neutral rating and raised the price target from $135 to $175 on Nov. 21, 2024. This analyst has an accuracy rate of 68%.</li>
<li>TD Cowen analyst Max Rakhlenko maintained a Buy rating and boosted the price target from $165 to $195 on Nov. 21, 2024. This analyst has an accuracy rate of 64%.</li>
</ul>
Considering buying WSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-1024x590.png" alt="" class="wp-image-819195" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11123018/image-69.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

Pre-Market Outlook

Williams-Sonoma Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

HUYA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>) reported quarterly sales of $204.93 million which missed the analyst consensus estimate of $215.25 million by 4.80 percent. This is a 4.89 percent decrease over sales of $215.47 million the same period last year.

Earnings Misses

HUYA Q4 Sales $204.93M Miss $215.25M Estimate

Press Releases

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Publishes 2024 Annual Report

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Comments

Genmab

Genmab (GMAB) 옵션

Genmab (NASDAQ:GMAB) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌